In terms of tolerability, ozanimod compares favorably with other sphingosine-1-phosphate receptor modulators [1–3]*. In the pivotal studies, drop-out rates due to adverse events were approximately 3%, with comparable rates in each of the different treatment groups. The adverse drug reactions most commonly observed during ozanimod therapy were nasopharyngitis, upper respiratory tract infections, urinary tract infections, elevated alanine aminotransferase and γGT levels, hypertension, and headache.
You May Also Like
- PancNEN, PancNET & PancNEC
Neuroendocrine tumors of the pancreas
- Heart failure
Interventional treatment of the tricuspid valve
- Lipoprotein(a)
Current and future treatment options
- Lichen sclerosus
Topical corticosteroids still the first choice
- Breast Cancer
On the trail of triple-negative breast cancer
- Headache treatment
The therapy of migraine
- Sleep disorders in old age
Recognize insomnia, treat it and avoid cognition disorders
- From symptom to diagnosis